MBC Advocate, following MBC breakthroughs
NYC
Joined October 2022
- Tweets5.1K
- Following1K
- Followers1.4K
- Likes15.7K
VIKTORIA-2 Enrollment is ongoing in the Phase 3 VIKTORIA-2 clinical trial that is evaluating gedatolisib combined w/ palbociclib and fulvestrant in the first-line setting for patients w/endocrine resistant HR+/HER2- metastatic breast cancer. $CELC #SABCS26 globenewswire.com/news-relea…
Olema will present: Palazestrant (OP-1250) in combination with atirmociclib, a phase 1b study, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer. $OLMA #SABCS26 stocktitan.net/news/OLMA/ole…
ARV-6723, Arvinas’ first immuno-oncology degrader.
Phase 1 trial will evaluate ARV-6723 as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, metastatic breast cancer. $ARVN #SABCS26 ir.arvinas.com/news-releases…
Phase 1/2 clinical trial of ARV-6723, an investigational, oral PROteolysis TArgeting Chimera (PROTAC) designed to degrade hematopoietic progenitor kinase 1 (HPK1) in advanced solid tumors, metastatic breast cancer. $ARVN #SABCS26 ir.arvinas.com/news-releases…
Palazestrant (OP-1250) in combination with everolimus, a phase 1b/2 study, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer. $OLMA #SABCS26 firstwordpharma.com/story/83…
A phase 1 study of OP-3136, a novel oral selective KAT6A/B inhibitor, as monotherapy and in combination w/ endocrine therapy (ET) in estrogen receptor-positive (ER+), human epidermal growth factor-2-negative (HER2-) metastatic breast cancer. $OLMA #SABCS26 globenewswire.com/news-relea…
Avenzo Therapeutics will present preliminary results from its Phase 1 ORION-1 study of AVZO-023, a novel, selective CDK4 inhibitor, metastatic breast cancer, at the 2026 San Antonio Breast Cancer Symposium. #SABCS26
Country singer Nicole Taylor has passed away at just 35 from metastatic breast cancer. Diagnosed with early-stage breast cancer at 31, Nicole went into remission, but heartbreakingly, her cancer returned as Stage IV MBC.
She became a voice for young women living with MBC #SABCS26
Puma ALISCA - Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer. $PBYI #SABCS26 #JPM27 businesswire.com/news/home/2…
NEW MBC Clinical Trial MEKanistic Therapeutics: First-in-Human Phase 1, Open-label Study to Evaluate the Safety, Clinical Activity, Pharmacokinetics & Pharmacodynamics of MTX-531 a Dual EGFR/PI3K Inhibitor as Monotherapy in Adults w/ Advanced Solid Tumors Metastatic Breast Cancer
Monitoring PD-L1 changes in circulating tumor-associated immune cells following initiation of immunotherapy may provide information regarding clinical benefit in pts w/MBC & are consistent w/findings reported in Bria-IMT Phase 2 study $BCTX $BCTXL #ESMO26 morningstar.com/news/globe-n…
Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01. #ESMO26 #BCAM prnewswire.com/news-releases…
“Efficacy, safety, and biomarker analysis of DB-1310 (HER3-targeted ADC) in pretreated HR+/HER2- metastatic breast cancer: Updated global phase 1/2a trial” #ESMO26 #BCAM scri.com/news/sarah-cannon-r…
The US Oncology Network, will present “Real world (RW) outcomes in HR+/HER2- metastatic breast cancer (MBC) patients, by second-line (2L) treatment” #ESMO26 #BCAM scri.com/news/sarah-cannon-r…
The US Oncology Network will present “First-in-class Rac/Cdc42 inhibitor MBQ-167 in patients with metastatic breast cancer (MBC): safety and preliminary efficacy” #ESMO26 #BC scri.com/news/sarah-cannon-r…
Findings from analysis of metastatic breast cancer patients support further evaluation of circulating CAML PD-L1 as a potential biomarker of clinical benefit from immunotherapies, including BriaCell’s earlier Phase 1/2 Bria-IMT study. $BCTX $BCTXL #ESMO26 biospace.com/press-releases/…
Dynamic changes in PD-L1 expression on circulating cancer-associated macrophage-like cells (CAML) were significantly associated w/ progression-free survival and overall survival following immunotherapies including the BriaCell regimen. $BCTX $BCTXL #ESMO26 investingnews.com/briacell-a…
Overall survival favored abemaciclib plus fulvestrant after disease progression on prior CDK4/6i & endocrine therapy. Numerically longer mOS 32 m. vs 25 m. Updated PFS, PFS2 & chemo-free survival all favored abemaciclib plus fulvestrant. $AZN $LLY #ESMO26 mededgemea.com/new-cancer-tr…
Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy. $AZN $LLY #ESMO26 #BCAM annalsofoncology.org/article…
